SecBot SecBot
8-K ·Filed Jun 4, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001193125-26-256458
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

The convertible note offering provides $243M in net cash to fund operations and pipeline development, reducing near-term financing risk. However, potential dilution of up to ~13.6M shares (roughly 8-10% of current shares outstanding based on $1.6B market cap) creates overhang. Monitor the stock price relative to the $24.76 conversion price, if SNDX trades above that level, conversion risk increases. The 2.25% coupon is low-cost debt for a biotech, but the 35% premium suggests management sees upside. Watch for the closing on June 10 and any subsequent use-of-proceeds announcements.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$18.02
T+0 close · Jun 4, 2026 · via day close
Latest settled
+8.44%
T+60 · $19.54
Vs SPY
+6.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $18.02entry
  2. T+1 · 6mo ago −3.77%α −1.18% · $17.34
  3. T+5 · 5mo ago −0.61%α +1.94% · $17.91
  4. T+20 · 4mo ago +21.09%α +22.46% · $21.82
  5. T+60 · 3mo ago +8.44%α +6.55% · $19.54

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, expected to close on June 10, 2026. Net proceeds of approximately $243 million will be used for general corporate purposes including R&D, commercialization, and business development. The notes carry a 35% conversion premium over the June 3 closing price and are senior unsecured obligations maturing in 2031.

Key Financial Metrics

Offering Size
$250.0M

Key Facts

  • $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
  • Net proceeds estimated at approximately $243 million
  • Initial conversion price of approximately $24.76 per share, a 35% premium over the last reported sale price on June 3, 2026
  • Notes mature June 15, 2031, interest payable semi-annually at 2.25%
  • Company may not redeem notes prior to June 20, 2029
  • Maximum of 13,631,400 shares of common stock issuable upon conversion based on initial maximum conversion rate
  • Sale expected to close June 10, 2026, subject to customary closing conditions
  • J. Wood Capital Advisors LLC acting as sole placement agent

Financial Impact

$250M principal raised, ~$243M net proceeds after fees and expenses

debtdilutioncash

Risk Factors

  • Potential dilution of up to 13.6M shares upon conversion, representing meaningful overhang
  • Interest expense of ~$5.6M annually adds fixed cost to a commercial-stage biotech still scaling revenue
  • If stock price declines, notes could still be converted under alternative conditions (trading price <98% of parity), accelerating dilution
  • Proceeds used for general corporate purposes provides limited visibility on capital allocation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-256458
Document: d65010d8k.htm0001193125-26-256458
Document: d65010dex991.htm0001193125-26-256458
Document: 0001193125-26-256458-index-headers.html0001193125-26-256458
Document: 0001193125-26-256458-index.html0001193125-26-256458
Document: 0001193125-26-256458.txt0001193125-26-256458

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026